Display options
Cite
Sefidi MD, Rasooli I, Owlia P, et al. Adjuvant role of Pseudomonas flagellin for Acinetobacter baumannii biofilm associated protein. World J Methodol. 2016;6(3):190-9doi: 10.5662/wjm.v6.i3.190.
Sefidi, M. D., Rasooli, I., Owlia, P., Talei, D., Astaneh, S. D., & Nazarian, S. (2016). Adjuvant role of Pseudomonas flagellin for Acinetobacter baumannii biofilm associated protein. World journal of methodology, 6(3), 190-9. https://doi.org/10.5662/wjm.v6.i3.190
Sefidi, Mozhgan Derakhshan, et al. "Adjuvant role of Pseudomonas flagellin for Acinetobacter baumannii biofilm associated protein." World journal of methodology vol. 6,3 (2016): 190-9. doi: https://doi.org/10.5662/wjm.v6.i3.190
Sefidi MD, Rasooli I, Owlia P, Talei D, Astaneh SD, Nazarian S. Adjuvant role of Pseudomonas flagellin for Acinetobacter baumannii biofilm associated protein. World J Methodol. 2016 Sep 26;6(3):190-9. doi: 10.5662/wjm.v6.i3.190. eCollection 2016 Sep 26. PMID: 27679782; PMCID: PMC5031927.
Copy Download .nbib Format: NLM
Share it on

World J Methodol. 2016 Sep 26;6(3):190-9. doi: 10.5662/wjm.v6.i3.190. eCollection 2016 Sep 26.

Adjuvant role of Pseudomonas flagellin for Acinetobacter baumannii biofilm associated protein.

World journal of methodology

Mozhgan Derakhshan Sefidi, Iraj Rasooli, Parviz Owlia, Daryush Talei, Shakiba Darvish Alipour Astaneh, Shahram Nazarian

Affiliations

  1. Mozhgan Derakhshan Sefidi, Iraj Rasooli, Department of Biology, Shahed University, Tehran 3319118651, Iran.

PMID: 27679782 PMCID: PMC5031927 DOI: 10.5662/wjm.v6.i3.190

Abstract

AIM: To study immunogenicity of Pseudomonas N terminal flagellin as an adjuvant for Acinetobacter baumannii (A. baumannii) biofilm associated protein (Bap).

METHODS: The N terminal flagellin gene was amplified. The pET28a (+) and polymerase chain reaction products were digested with HindIII and EcoR I. The ligation of N terminal flagellin into pET28a (‏+) was performed using T4 DNA ligase and was then transformed into Escherichia coli BL21 (DE3) as a suitable expression host. pET28a (‏+) vector harboring a conserved region of Bap from our previous work was used. The recombinant proteins were expressed, analyzed by SDS-PAGE method and was purified by affinity chromatography with His-Tag residues followed by confirmation with western blotting. Mice were immunized with recombinant N terminal flagellin and Bap subunits. The immunized animals were intranasally (i.n) challenged with A. baumannii and Pseudomonas aeruginosa (P. aeruginosa).

RESULTS: The flagellin enhanced the immunogenicity of Bap causing an increase in specific IgG titers in serum (P < 0.001). Internal organs, i.e., liver, lung and spleen of the Bap-Flagellin immunized group challenged with A. baumannii showed significantly lower bacterial load compared to the control group. The bacterial loads were studied in internal organs. A. baumannii infected immunized animals with Bap-Flagellin exhibited internal organs with minor bacterial load while P. aeruginosa PAO1 infected group showed heavy bacterial load of (4.3 ± 0.12) × 10(6), (1.1 ± 0.01) × 10(6) and (2.2 ± 0.22) × 10(6) per gram of lungs, liver and spleen respectively. Bacterial loads were detected per gram of lungs, liver and spleen of the mice group immunized with Bap were (1.2 ± 0.06) × 10(7), (11.1 ± 0.041) × 10(5) and (3.6 ± 0.42) × 10(6) respectively. In vivo neutralization assay indicated that all experimental mice groups, except for Flagellin administered group was significantly (P < 0.05) protected against A. baumannii.

CONCLUSION: These results demonstrate that P. aeruginosa Flagellin as an adjuvant for Bap A. baumannii could be a useful model to evaluate new vaccine against A. baumannii.

Keywords: Acinetobacter baumannii; Biofilm associated protein; Immunogen; Pseudomonas aeruginosa; Vaccine

Conflict of interest statement

Conflict-of-interest statement: The authors declare no conflict of interests.

References

  1. Vaccine. 2007 Jan 8;25(4):763-75 - PubMed
  2. Vaccine. 2010 Feb 3;28(5):1373-82 - PubMed
  3. Int J Antimicrob Agents. 2010 Mar;35(3):219-26 - PubMed
  4. Infect Immun. 2005 Mar;73(3):1706-13 - PubMed
  5. Annu Rev Immunol. 2003;21:335-76 - PubMed
  6. J Theor Biol. 2010 Sep 21;266(2):275-90 - PubMed
  7. J Bacteriol. 2008 Feb;190(3):1036-44 - PubMed
  8. J Bacteriol. 2009 Oct;191(19):5953-63 - PubMed
  9. J Bacteriol. 2001 May;183(9):2888-96 - PubMed
  10. Microb Pathog. 2011 Dec;51(6):402-6 - PubMed
  11. J Clin Microbiol. 1997 Jun;35(6):1394-7 - PubMed
  12. Science. 2005 Jun 10;308(5728):1626-9 - PubMed
  13. Indian J Med Microbiol. 2008 Oct-Dec;26(4):333-7 - PubMed
  14. Vaccine. 2002 May 31;20 Suppl 3:S56-64 - PubMed
  15. Microbiology. 2003 Dec;149(Pt 12):3473-84 - PubMed
  16. Vaccine. 2010 Apr 1;28(16):2818-26 - PubMed
  17. Infect Immun. 2012 Feb;80(2):651-6 - PubMed
  18. J Immunol. 2001 Jan 15;166(2):1248-60 - PubMed
  19. Enferm Infecc Microbiol Clin. 2008 Apr;26(4):185-6 - PubMed
  20. J Bacteriol. 2003 Jul;185(14):4243-7 - PubMed
  21. Infect Immun. 2009 Aug;77(8):3150-60 - PubMed
  22. Vaccine. 2013 Feb 6;31(8):1210-6 - PubMed
  23. Vaccine. 2008 Dec 9;26(52):6777-83 - PubMed
  24. Clin Microbiol Rev. 1996 Apr;9(2):148-65 - PubMed
  25. J Biotechnol. 1999 Jul 30;73(1):1-33 - PubMed
  26. Trends Microbiol. 2009 Feb;17(2):73-87 - PubMed
  27. Biochem Biophys Res Commun. 2013 Oct 25;440(3):437-42 - PubMed
  28. Nucleic Acids Res. 2003 Jul 1;31(13):3784-8 - PubMed
  29. Nat Immunol. 2003 Dec;4(12):1247-53 - PubMed
  30. Nat Immunol. 2004 Oct;5(10):987-95 - PubMed
  31. Nat Rev Drug Discov. 2003 Sep;2(9):727-35 - PubMed
  32. Vaccine. 2012 Aug 31;30(40):5856-63 - PubMed
  33. J Clin Microbiol. 1998 Jul;36(7):1938-41 - PubMed
  34. J Hosp Infect. 2009 Dec;73(4):355-63 - PubMed
  35. J Biol Chem. 2002 Oct 25;277(43):40456-61 - PubMed
  36. Clin Vaccine Immunol. 2008 Feb;15(2):367-75 - PubMed

Publication Types